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Studies in some parts of the world have shown that Anti-R7V antibodies, which neutralize 100% of the 
different variant’s panel (targeted against a beta2-microglobulin epitope acquired when the virus is 
released by budding) in vitro, are found in 30 to 50% of naïve HIV positive patients, but even more in so-
called “long-term survivor’’ patients with a close to 90% correlation. The seroprevalence of Anti-R7V 
antibody was therefore investigated in HIV patients attending clinic within the Federal Capital Territory 
(FCT) and compared with HIV negative patients. Correlation between the presence of the antibody and 
the clinical status of patients was also investigated. The HIV positive patients were categorized into 
drug naïve and drug experienced subjects and their Anti-R7V antibody together with CD4 counts were 
determined using Anti-R7V ELISA kits and BD FACS count, respectively. About 47.2% of the HIV-
infected patients tested positive for the Anti-R7V antibody while 25.2% were negative for this antibody. 
Patients with Anti-R7V antibody had a mean CD4 count (355 ± 19.2) significantly (P < 0.05) higher than 
that of Anti-R7V antibody negative patients (215 ± 42.6). Also it was observed that Anti-R7V antibody 
was significantly (P < 0.05) lower in drug experienced patients as compared to drug naïve patients. The 
significance of these findings is discussed. It was concluded that Anti-R7V antibody may be a natural 
immunity against HIV-infection in drug naïve HIV patients and that the synthesis and release of this 
antibody may decrease with ARD treatment. 
 





Since the first reported cases of HIV/AIDS in the early 
1980s, HIV has emerged as one of the most significant 
infectious agents, infecting approximately 40 million 
people worldwide (UNAIDS, 2002). The key to the patho-
genicity of this virus is its genetic heterogeneity, which is 
the result of several features namely the error-prone 
enzyme reverse transcriptase (RT), which is estimated to 
introduce an average of one error per genome per 
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1995) and the rapid turnover of HIV- 1 in vivo (Ho et al., 
1995), recombination which occurs at a rate of about 2% 
per kilobase per replication cycle (Temin, 1993; 
Subbarao and Schochetman, 1996) with its selective 
immune pressures by the host (Micheal, 1999). At pre-
sent HIV is classified on the basis of genetic difference 
and similarities into types, group and sub types (Reeves 
and Dom, 2002). 
Since the first case of AIDS diagnosed in Nigeria, in a 
13 year-old girl in 1986 (National Guideline on Prevention 
of Mother to Child Transmission in Nigeria,  2005), HIV 
prevalence has been on the  increase from 1.8% in 1991 
to 5.8% in 2001 and declined to 5.0% in 2003 and 4.4% 
in 2005. The 2005 survey showed State  prevalence  vary  
 




from as low as 1.6% in Ekiti State to  as  high  as  10%  in 
Benue state and with 15 state including the FCT having 
prevalence above the national average of 4.4%. Women 
are believed to be more severely affected than men 
(National HIV/Syphilis Sentinel Seroprevalence Survey of 
2005). 
The existence of asymptomatic patients showing non-
progression for more than 10 years raises the question of 
a possible natural AIDS resistance mechanism. It has 
been reported that anti-R7V antibodies, which neutralize 
100% of the different variant’s panel (targeted against a 
beta2-microglobulin epitope acquired when the virus is 
released by budding) in vitro, are found in 30 to 50% of 
naïve HIV positive patients, but even more in so-called 
“long-term survivor’’ patients with a close to 90% 
correlation (Galea  et al., 1996). 
The CD4 lymphocyte count has demonstrated 
variability, even in the same patient, the variation can be 
more than 100/L cells in the same day due to diurnal 
variations. Additional laboratory testing factors that play a 
role in measurement of CD4 lymphocytes include 
variations in total white blood cell count, lymphocyte 
percentage and CD4 percentage. Physiologic factors 
may include exercise as well as consumption of tobacco, 
alcohol and caffeine (Raboud et al., 1995).  
The anti-R7V antibodies have been linked to non 
progression of HIV-infected patients to full blown AIDS. 
Correlation of the presence of the protective anti-beta2 
microglobin derived peptide antibodies with non progre-
ssion to AIDS has been reported in France (Galea et al., 
1996). However, no information has been documented 
regarding the prevalence of this antibody in long term non 
progressors in Nigeria. Thus, the objectives of this study 
were to determine the prevalence of neutralising anti-R7V 
antibodies in the sera of HIV- infected persons within the 
FCT and some neighbouring towns, determine the 
prevalence of neutralising anti-R7V antibodies in the sera 
of HIV-infected persons on anti-retroviral drugs, and to 








A total of 176 randomly diagnosed HIV positive patients attending 
HIV clinic at Asokoro District Hospital were used for the study. The 
176 HIV patients included those on Antiretroviral drugs (ARDs) and 
drug naive. In addition, 88 randomly selected apparently healthy 
subjects who after being screened tested negative for HIV antibody 
were used as control.  
 
 
Area of study 
 
The study was conducted using data and blood specimen collected 
from patients attending HIV clinics at Asokoro District Hospital in 
the FCT. The FCT was chosen as the study area because of its 
location within a zone (North Central) that has the highest 
prevalence of HIV and the highest population growth rate (10% per 







Informed consent and approval was obtained from the Asokoro 
District Hospital’s Management and its Ethical Committee. The 




Collection of specimens  
 
Two to three mililitres (2 to 3 ml) of blood was collected from the 
median cubital vein of each subject into EDTA vacutainers and 
centrifuged to obtain the plasma. The plasma obtained was stored 
at -200C until needed for assay. 
 
 
Anti-R7V ELISA Kits 
 
The Anti-R7V ELISA test was purchased from the manufactures, 






Blood samples were collected from HIV positive patients on anti 
retro viral drugs (ARV) and those recently diagnosed but not on 
ARV treatment. The following assays were carried out on blood 
samples obtained from each subject: 
 
1. Screening for HIV. 
2. CD4 count 
3. Anti-R7V Antibodies. 
 
 
Screening for HIV antibody 
 
The screening for HIV was performed using 2 types of HIV test kits 
per sample namely CHEMBIO HIV1/2 STAT-PAK® ASSAY and 





The BD FACSCount™ reagent kits which contain CD4 PE/CD3 PE-
Cy5 tubes (green top), CD8 PE/CD3 PE-Cy5/CD3 tubes (clear top) 
and 220 reagent tube caps were used to enumerate the absolute 
counts of CD4 of unlysed whole blood, using the BD FACSCount 
instrument. This will provide information on the immune status of 
the patients with the human immunodeficiency virus. The CD4/ CD3 
tube determines the absolute number of helper/inducer T 
lymphocytes. The CD8/CD3 tube determines the absolute number 
of suppressor/cytotoxic T lymphocytes. Both tubes measure the 




ANTI-R7V antibody  
 
The Anti-R7V ELISA is a serological test (90 min) based on an 
immunoenzymatic assay. The assay allows the detection of the 
presence of antibodies directed against the R7V epitope in serum 
or plasma samples of individuals detected as being seropositive for 
HIV infection. Microplate wells that were coated in a covalent and 
homogeneous way with peptidic fragments containing the sequence 
R7V allowed the specific capture of anti-R7V antibodies which were 
present in the samples of serum or plasma. Their colorimetric 
revelation was made after addition of an enzymatic conjugate (Goat  
 

































anti-human IgG coupled to horse radish peroxidase containing 
0.5% Proclin 300 ) and 12 mL of an enzymatic chromogen 
substrate (3,3’,5,5’ tetramethylbenzidine TMB). The optical density 
(OD) values were read at 450 nm within 15 min of adding the stop 
solution (diluted hydrochloric acid). After subtraction of the sample 
blank, the mean OD value observed for each of the patient samples 
was normalized on the mean OD value of the internal calibrator. 
The conclusion as for the presence or the absence of anti-R7V 





The distribution of the 176 subjects diagnosed as HIV 
positive as presented in Figure 1, shows that 123 (68.9%) 
were females while 53 (30.1%) were males. In the 88 HIV 
negative subjects 34 (38.6%) were males and 54 (61.4%) 
females. 
Figure 2 shows the distribution of HIV positive patients 
according to their age groups. The data obtained showed 
that the age bracket 27 - 36 yrs had the highest number 
of HIV-infected patients representing 50% of the total 
population, this was followed by the age brackets 37 - 46, 
17 - 26 yrs which had (23.3%) and (19.3%), respectively. 
It was observed that the age brackets of 47 - 56, 57 - 66 
and 67 - 76 had HIV- infected patients’ population of 
below 5% while the age group of 17-46 accounted for 
92% of the infected population. 
The result of the prevalence of anti-R7V antibody in the 
sera of HIV- infected patients is presented in Figure 3. Of 
the total population of the infected patients 83 (47.2%) 
tested positive for anti-R7V antibody while 45 (25.6%) 
were negative for this antibody. The remaining 48 
subjects fell within the grey zone, that is, having titer 
value ratio of (ODsample/ODCAL) 0.8 - 1.0. Also, of the 
population that tested positive for anti-R7V antibody, 
females had remarkably higher percentage; that is, (61) 
73.5% positive against (22) 26.5% positive males. There 
was however, no significant (P > 0.05) difference in anti-
R7V antibody between male and female HIV- infected 
patients. 
The prevalence of anti-R7V antibody in the sera of the 
88 HIV negative subjects as shown in Figure 4 shows 1 
(1.1%) positive, 2 (2.8%) grey and 31 (35.2%) negative 
for males against 2 (2.8%) positive, 3 (3.4%) grey and 49 
(55.7%) negative females.    
The relationship between anti-R7V antibody and CD4 
count as presented in Figure 5, depicted patients that are 
anti-R7V positive had a mean CD4 count of 355.6 ± 19.2.  
 




















































Figure 3. Seroprevalence of Anti-R7V antibody in HIV infected patients. 
 





























The data showed that 19 (22.9%) of the anti-R7V positive 
antibody patient had a CD4 count of below 200 while 52 
(62.7%) had CD4 count of 200 - 499 and 12 (14.5%) had 
CD4 count of 500 and above. On the test of 
independence of Anti-R7V antibody and CD4 count, the 
significant value of 0.08 may be adjudged significant 
since 92% confidence coefficient is high enough to 
indicate that CD4 count depends on Anti-R7V    
The distribution of mean CD4 count according to age 
groups as shown in Figure 6 indicates the age bracket 17 
- 26 yrs having the highest mean CD4 count of 404.9 ± 
37.5 followed by 26 - 36 and 37 - 46 yrs with mean CD4 
count of 356.9 ± 27.9 and 329 ± 24.5, respectively. 
However the age bracket 27 - 36 had the highest number 
of patients 18 patients (10.6%) with CD4 count of above 
500 and also those with CD4 count of between 200 – 
499, that is, 36 (21.2%). Patients in the age bracket 17 – 
26 yrs had 7 (4.1%) with CD4 count of above 500 and 19 
(11.2%) with CD4 count of between 200 - 499. Similarly 
the age group 27 - 36 had the highest number of patients 
with CD4 count of below 200, 33 subjects (19.4%) 
followed   by   the   age  group   37 - 46  with 16  subjects   
(9.41%) and 17 - 26 having 8 subjects (4.71%). 
The relationship between CD4 count and sex is shown 
in Figure 7. The male patients had a mean CD4 count of 
349.2 ± 26.1 against the female mean of 371 ± 22.2. 
Furthermore the female with CD4 count of between 200 - 
499 were 53 (30.3%) patients and 26 (14.9%) with CD4 
count of above 500. In the male patients those with CD4 
count of between 200 - 499 were 28 (16.0%) while 9 
(5.1%) had CD4 count of above 500. The test for 
dependence of CD4 count and sex was not significant (P 
> 0.05), that is, CD4 count does not depend on sex. 
Figure 8 shows the relationship between the presence 
of the Anti-R7V antibody with treatment status, that is, on 
drugs (ARDs) and drug naïve patients. There were only 
12 (14.5%) drug experienced patients who tested positive 
for the presence of the anti R7V antibody as against 73 





The results of this study showed the population of  female  
 































































Figure 6. Relationship between age and CD4 count. 
 



























































Figure 8. Relationship between status of patients and Anti-R7V antibody. 
 




is far more affected when compared to males and the 
age group with the highest prevalence rate falls between 
the age brackets of 17 - 46 years. This is in agreement 
with the WHO statistics for Nigeria in 2005 which showed 
that the age bracket 15 - 49 yrs had the highest percen-
tage distribution of HIV positive patients (WHO/UNAIDS, 
2005).    
Merson (2006) from his work stated that “At the start of 
the 21st century, 95% of new HIV infections and deaths 
occurred in developing nations and two thirds of persons 
living with HIV infection resided in sub-Saharan Africa. 
The age group most affected, young persons from 15 to 
24 years of age, accounted for 40% of new HIV infections 
Worldwide”. While Quinn (1996) showed that over half 
the victims of AIDS are women and a consequence of 
this is perinatal infection resulting in a significant number 
of children born with HIV infection.   
About 48% of the population had the Anti-R7V anti-
body. This result is in line with the work of Chermann 
(2002) who found that only 35 - 65% of HIV- infected 
patients seem to develop specific antibody against the 
R7V epitope. From his work in France, 30% of the HIV 
population carry anti-R7V antibodies, in Malaysia 20%  of 
the 200 tested patients had the antibody, while in the US, 
they found 50% of black HIV patients, 38% of Haitians, 
30% of Caucasians and Hispanics and 25% Asians had 
the Anti-R7V antibodies.  
The presence of the anti-R7V antibodies in individuals 
was correlated with treatment status of patients. The 
result from this study shows that in the treated population 
14.8% had the antibody as against 85.2% of drug naïve 
population having the antibody. The observation of a 
significantly (P < 0.05) high percentage population of 
patients who are sero positive to anti-R7V antibody in 
drug naïve patients, may suggest that the synthesis of 
this antibody and its secretion into blood circulation may 
be related to the viral load. In the patients under 
treatment the drug may have reduced the viral load, that 
is, degree of infection. Consequently the patient’s 
immune system may have reduced the rate at which the 
antibody is synthesized and released into circulation. This 
finding is in line with previous report of Chermann (2002) 
that the Anti-R7V antibody disappears with treatment. 
The disappearance of this antibody is attributed to the 
fact the anti-R7V antibody is a natural immunity that is 
acquired when the body is exposed to the HIV.  
The CD4 count is a reflection of how many functional 
CD4 T-cells is circulating in the blood. CD4 cell tests are 
normally reported as the number of cells in a cubic 
millimeter of blood, or mm3. A standard reference range 
is not available for this test because the value bounces a 
lot as factors like, time of day, fatigue, stress, and test 
method can affect the test results and also numeric test 
results have different meanings in different laboratory.  
The normal CD4 cell count for most laboratories is a 
mean of 800 to 1050/mm3, with a range representing two 





(Hughes et al., 1994). The wide range in normal values 
reflects the fact that the CD4 cell count is the product of 
three variables: the white blood cell count, the percent 
lymphocytes and the percent lymphocytes that bear the 
CD4 receptor. CD4 cells are reduced precipitously with 
acute HIV-infection, but may rebound over several weeks 
and then progressively decline over several years. CD4 
cells determination is important in the stage evaluation of 
patients with HIV infection as it provides guidelines for 
differential diagnosis of complications and to guide both 
antiviral therapy and prophylaxis for opportunistic patho-
gens. The CD4 cell count is also a relatively consistent 
indicator of the response to antiretroviral therapy 
(Graham et al., 1995)  
The Center for Disease Control and Prevention (CDC) 
defined a set of guidelines and recommendations for HIV-
infected adolescents and adults on the basis of clinical 
conditions associated with the HIV infection and CD4 T 
lymphocyte counts (CDC, 1988; CDC, 1993; CDC, 1997). 
The system is based on 3 ranges of CD4 T-lymphocyte 
counts (> 500, 200 – 499, < 200) or CD4% and 3 clinical 
categories and is represented by a matrix of 9 mutually 
exclusive categories. This complex yet comprehensive 
case definition of AIDS enables the clinician to view HIV 
disease as a spectrum ranging from primary acute phase 
to advanced clinical disease and thus plays an important 
role in AIDS surveillance (CDC, 1993) 
This study went further to correlate anti-R7V antibody 
with CD4 count and the result showed a mean CD4 count 
of 350 ± 19.2 with the presence of the Anti-R7V antibody. 
This result is in agreement with preceding studies (Galea 
et al., 1996; Galea et al., 1999; Haslin and Chermann, 
2006; Maggiore, 2007) that postulated that subjects who 
have anti-R7V antibodies have lower likelihood of 
progressing to AIDS, because R7V epitope with which 
the antibody combines, is acquired by the HIV virus while 
budding from an infected cell. The anti-R7V antibody 
adheres to the R7V epitope on its surface and as the 
structure of the HIV envelope is changed it prevents the 
virus from entering healthy immune system cells thereby 
neutralizing the HIV.  
This study found no relationship between presence of 
anti R7V antibody and age or sex. Information is scarce 
in the literature on the relationship of Anti-R7V antibody 





1. It is concluded from this study that the seroprevalence 
of Anti-R7V antibody is higher in HIV patients who are 
drug naïve when compared with drug experienced and 
HIV negative individuals.   
2. It is also concluded that that there is a positive 
correlation between stable CD4 counts of HIV infected 
patients with Anti-R7V antibody. 






HIV-infection in drug naïve HIV patients and that the 
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